Merck KGaA (OTCMKTS:MKGAF) Shares Gap Down – Time to Sell?

Shares of Merck KGaA (OTCMKTS:MKGAF – Get Free Report) gapped down prior to trading on Tuesday. The stock had previously closed at $167.12, but opened at $160.60. Merck KGaA shares last traded at $169.40, with a volume of 4 shares traded.

Merck KGaA Trading Down 0.1%

The company has a market cap of $21.90 billion, a PE ratio of 25.87 and a beta of 0.96. The business has a 50 day simple moving average of $161.24 and a two-hundred day simple moving average of $152.37. The company has a current ratio of 1.31, a quick ratio of 0.84 and a debt-to-equity ratio of 0.27.

Hedge Funds Weigh In On Merck KGaA

Several large investors have recently added to or reduced their stakes in the business. Elefante Mark B acquired a new stake in Merck KGaA in the 2nd quarter worth about $617,000. Ames National Corp purchased a new stake in Merck KGaA in the 2nd quarter valued at about $1,009,000. Notis McConarty Edward acquired a new position in shares of Merck KGaA during the 2nd quarter valued at about $1,304,000. North Star Asset Management Inc. acquired a new position in shares of Merck KGaA during the 2nd quarter valued at about $1,411,000. Finally, Pinnacle Holdings LLC acquired a new position in shares of Merck KGaA during the 2nd quarter valued at about $1,487,000. 0.10% of the stock is currently owned by hedge funds and other institutional investors.

Merck KGaA Company Profile

(Get Free Report)

Merck KGaA is a science and technology company headquartered in Darmstadt, Germany. Founded in 1668, it is distinct from the U.S.-based Merck & Co. and operates internationally across healthcare, life science and electronics. Its Healthcare business develops prescription medicines, including treatments in areas such as oncology, neurology, immunology and fertility. The Life Science business supplies products and services used in research, biotechnology and pharmaceutical manufacturing, including laboratory materials, equipment and solutions for bioprocessing.

Featured Articles

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.